Lupin Limited

Pharmaceutical Contract Research and Manufacturing (CRAM) Market size to grow by USD 121.35 billion from 2022 to 2027; Asia to account for 41% of market growth - Technavio

Retrieved on: 
Tuesday, January 16, 2024
ChromeOS, Catalent, Recipharm, Parexel, ROW, Geography, Biotechnology, Syneos Health, Thermo Fisher Scientific, ICON PLC, ICON, CMO, CRAM, USD, Free, Lupin Limited, Research, IQVIA, Growth, Fine chemical

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The pharmaceutical contract research and manufacturing (CRAM) market is expected to grow by USD 121.35 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The pharmaceutical contract research and manufacturing (CRAM) market is expected to grow by USD 121.35 billion from 2022 to 2027.
  • In addition, the momentum of the market will progress at a CAGR of 10.32% during the forecast period, according to Technavio Research.
  • For additional data on Market Size (2017) Historic Year, Market Size - Forecasted Year, Historic Opportunity (2017-2021), Historic CAGR, Forecasted Opportunity (2023-2027), Market Opportunity Transformation Growth, and Market Opportunity Capitalization.
  • Pharmaceutical Contract Research And Manufacturing (CRAM) Market: Segmentation Analysis
    The market share growth of the CMO segment will be significant during the forecast period.

Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada

Retrieved on: 
Tuesday, August 29, 2023
Capsule, Quality of life, Pharmacist, Lupin Limited, Patient, Pharmaceutical industry, Propranolol

MONTREAL, Aug. 29, 2023 /PRNewswire/ -- Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), today announced the launch of Propranolol LA (long-acting) capsules,60 mg, 80 mg, 120 mg and 160 mg, in Canada.

Key Points: 
  • MONTREAL, Aug. 29, 2023 /PRNewswire/ -- Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), today announced the launch of Propranolol LA (long-acting) capsules,60 mg, 80 mg, 120 mg and 160 mg, in Canada.
  • Propranolol LA is a generic equivalent of Inderal® LA, it provides an effective treatment solution since the discontinuation of Inderal® LA for patients and healthcare practitioners.
  • "We are delighted to announce the launch of Propranolol LA capsules for patients in Canada.
  • Lupin encourages patients to consult healthcare practitioners or pharmacists regarding the transition to Propranolol LA.

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Retrieved on: 
Friday, July 28, 2023
Amneal Pharmaceuticals, Damages, Lupin Limited, Class, Parent, Xywav, Nestlé USA, Inc. v. Doe, Person, Injunctive, District court, Settlement, Express Scripts, Court order, Punitive damages, Court, Defendant, City, Federal Employees Health Benefits Program, Tobacco, Insurance, Sodium oxybate

The plaintiffs in the lawsuit have reached a proposed Settlement with the Amneal and Lupin defendants that would resolve all claims against them.

Key Points: 
  • The plaintiffs in the lawsuit have reached a proposed Settlement with the Amneal and Lupin defendants that would resolve all claims against them.
  • Separately, the Court has certified several classes of Xyrem and/or Xywav payers and the claims of those classes against the remaining defendants will continue.
  • The proposed Settlement and the Court's class certification order may affect the rights of members of the Settlement Class, the Damages Class and the Injunctive Relief Class (all defined below).
  • But they give up any rights to sue the Defendants separately about the same legal claims in this lawsuit.

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth

Retrieved on: 
Tuesday, June 27, 2023
Vaccine, Teva Pharmaceuticals, Ludwig Maximilian University of Munich, Good, Executive, University, FP, CSO, Biotechnology, Education minister, Pfizer, Finance, RNA, AstraZeneca, Quality, Merck & Co., Lupinus, Protein, Lupin Limited, Machine learning, SAN, M.B.A, Drug discovery, CFO, Growth, Eli Lilly and Company, Artificial intelligence, Therapy, DVM, Automation, Management, Pharmaceutical industry, Science, Pharmacology

BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the appointments of Martin Brenner, DVM, Ph.D. as Chief Executive Officer; and Felipe Duran as Chief Financial Officer, effective immediately. Dr. Brenner will also continue to serve as iBio's Chief Scientific Officer, a role he has held since December 2020.

Key Points: 
  • Dr. Brenner will also continue to serve as iBio's Chief Scientific Officer, a role he has held since December 2020.
  • The permanent appointments reflect the Board of Directors’ confidence in Dr. Brenner and Mr. Duran, who have respectively served as iBio’s interim CEO and CFO since early 2023, to complete the strong management team required to lead the Company in its next stage of growth.
  • Martin and Felipe are the right people to lead iBio.
  • During his tenure at Lupin, Mr. Duran functioned as a key member for the Latin American executive team, supporting both Mexico and Brazil.

Lupin Pharma Canada announces the availability of Intrarosa® (prasterone vaginal ovules), a new treatment option in Canada for women with postmenopausal vulvovaginal atrophy

Retrieved on: 
Wednesday, January 25, 2023
Irritation, Menopause, Ovule, Finger, Intravaginal administration, Monograph, Dyspareunia, R, Lupin Limited, Personal lubricant, Woman, Patient, Birth control

Intrarosa® is a 100% Canadian, Quebec-based innovation, from R&D to manufacturing

Key Points: 
  • Intrarosa® is a 100% Canadian, Quebec-based innovation, from R&D to manufacturing
    MONTREAL, Jan. 25, 2023 /CNW Telbec/ - Lupin Pharma Canada, a wholly-owned subsidiary of Lupin Limited (Lupin), announced today the launch of Intrarosa® (prasterone vaginal ovules) for the treatment of postmenopausal vulvovaginal atrophy.
  • "It is a new option for women who suffer from the symptoms of menopause such as dyspareunia (painful intercourse), vaginal dryness, irritation, and itching.
  • "Lupin is dedicated to serving both patients and healthcare providers with high quality medicines that address patient needs and deliver value.
  • It offers a new treatment option to Canadian women with menopausal symptoms such as dyspareunia (painful intercourse), vaginal dryness, irritation, and itching," said Patrick Nadeau, General Manager of Lupin Pharma Canada.

Global Generic Drugs Market to Grow by $176.25 Billion During 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Health, Pharmaceutical, Sun Pharma, Novartis, Merck, Lupin Limited, Fresenius (company), Amgen, Endo International, Growth, Eli Lilly and Company, Abbott Laboratories, RPA, M. Levin & Co, Inc, Research, Pfizer, Viatris, Baxter International, Edel SE & Co. KGaA, GlaxoSmithKline, Fine chemical, Pharmaceutical industry

This study identifies the advent of RPA as one of the prime reasons driving the generic drugs market growth during the next few years.

Key Points: 
  • This study identifies the advent of RPA as one of the prime reasons driving the generic drugs market growth during the next few years.
  • Also, rising m and a and hospital-owned generics will lead to sizable demand in the market.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
  • The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Global Chronic Obstructive Pulmonary Disease Drugs Market to Grow by $66.54 Billion During 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
General Health, Pharmaceutical, Health, Chronic obstructive pulmonary disease, Novartis, Vertex Pharmaceuticals, Spondyloarthropathy, Lupin Limited, Smoking, AstraZeneca, Chiesi Farmaceutici, A.D. Bedell Wholesale Co., Inc. v. Philip Morris Inc., Research, Viatris, Philip Morris International, Dendrite International, Inc. v. Doe No. 3, GlaxoSmithKline

This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years.

Key Points: 
  • This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years.
  • Also, advances in drug delivery devices and the growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.
  • The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Four Lots of Quinapril Tablets due to potential presence of N-Nitroso-Quinapril Impurity

Retrieved on: 
Wednesday, December 21, 2022
Online, Lupin Limited, EST, Patient, Food, Knowledge, Supermarket, FDA, Completeness, Prescription, Multimedia, Pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, Merrell Dow Pharmaceuticals Inc. v. Thompson, Dietary supplement, Pharmaceutical industry

Patients taking, Quinapril Tablets USP, 20mg, and 40mg are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.

Key Points: 
  • Patients taking, Quinapril Tablets USP, 20mg, and 40mg are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.
  • Wholesalers, distributors and retailers that have Quinapril Tablets USP, 20mg, and 40mg that are being recalled should discontinue distribution of the recalled product lots immediately.
  • Consumers, wholesalers, distributors, and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (877) 538-8445 Monday – Friday 09:00 am to 05:00 pm EST.
  • Lupin Pharmaceuticals, Inc. is the U.S. based wholly-owned subsidiary of Lupin Limited and is the 3rd largest pharmaceutical company in the U.S. based on total prescriptions.

The Global Addison's Disease Therapeutics Market is expected to grow by $442 mn from 2023-2027, accelerating at a CAGR of 6.93% during the forecast period

Retrieved on: 
Wednesday, November 30, 2022
Amgen, Bristol-Myers Squibb Co. v. Superior Court, Abbott Laboratories, Pfizer, Biogen, M. Levin & Co, Inc, Lupin Limited, Bayer, Neurocrine Biosciences, Degenerative disease, Eli Lilly and Company, Novartis, Bio-Techne, GlaxoSmithKline, Research, Therapy, Pharmaceutical industry

View original content:https://www.prnewswire.com/news-releases/the-global-addisons-disease-the...

Key Points: 
  • Also, the availability of clinical guidelines and redefined pathophysiology will lead to sizable demand in the market.
  • The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • Also, Addisons disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Leukemia Therapeutics Global Market Report 2022: A $20+ Billion Market in 2026 - Long-term Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 12, 2022
Pharmaceutical, Health, Oncology, GlaxoSmithKline, Therapy, Chronic lymphocytic leukemia, Immunotherapy, Lupin Limited, Texas Homecare, Prevalence, Exelixis, Asia-Pacific, Takeda Pharmaceutical Company, Organization, Acquisition, National, Growth, Leukemia, MorphoSys, Industry, Patient, Cancer, Acute leukemia, Bone marrow, Acute myeloid leukemia, Amgen, Pfizer, Bristol Myers Squibb, AbbVie, Celgene, Lymphatic system, Immune system, Hospital, National Cancer Institute, Medical device, Pharmaceutical industry, Oil, Trillium

The leukemia therapeutics market consists of sales of the leukemia therapeutics by entities (organizations, sole traders, and partnerships) that are used for the treatment of leukemia.

Key Points: 
  • The leukemia therapeutics market consists of sales of the leukemia therapeutics by entities (organizations, sole traders, and partnerships) that are used for the treatment of leukemia.
  • The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The leukemia therapeutics market research report is one of a series of new reports that provides leukemia therapeutics market statistics, including leukemia therapeutics industry global market size, regional shares, competitors with a leukemia therapeutics market share, detailed leukemia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the leukemia therapeutics industry.
  • Global Leukemia Therapeutics Market, Segmentation By Type Of Leukemia, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion